Ewing’s Sarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Ewing’s Sarcoma Therapeutics Market Forecast to Show Slow Growth, The report is an essential source of information and analysis on the global Ewing’s sarcoma market. GlobalData estimates that the global Ewing’s sarcoma therapeutics market was valued at $7.4m in 2010, and is forecast to grow at a slow pace with a compound annual growth rate (CAGR) of 3.4% over the next seven years to reach $9.4m by 2017. This slow growth is primarily attributed to the slow increase in the patient population and late diagnosis of the disease. The Ewing’s sarcoma therapeutics market is relatively small compared to other cancers, and untapped opportunity exists for companies with better disease cures and therapies with improved toxicity profiles. The current competition in the global Ewing’s sarcoma therapeutics market is weak, as there is only one approved drug, Cosmegen (dactinomycin), which is no longer in use due to its low safety and efficacy profiles. There are currently five off-label drugs such as Oncovin (vincristine), Adriamycin (doxorubicin), Cytoxan/Neosar (cyclophosphamide), Ifex (ifosfamide) and Vepesid (etoposide) which have been moderately effective in the treatment of Ewing’s sarcoma. Clearly there is a need for more effective and tolerable therapies for Ewing’s sarcoma. As a result, considerable opportunity exists for new treatment options to meet the unmet need. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Ewing-Sarcoma-TherapeuticsPipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Ind The only approved drug, Cosmegen (dactinomycin), has been largely replaced by other off-label drugs due to its low efficacy and safety. The Ewing’s sarcoma pipeline is strong, with all the molecules being first-in-class. These pipeline molecules may change the future treatment landscape for Ewing’s sarcoma. Some of the molecules in clinical development include ganitumab, cixutumumab, dasatinib (Sprycel), sunitinib (Sutent), Zalypsis and Yondelis. GlobalData’s analysis indicates that the unmet need for Ewing’s sarcoma treatment is high due to the lack of effective treatment. The current drug regimens used in the treatment of Ewing’s sarcoma have moderate efficacy and very low safety profiles. As a result, there is a need for drugs with novel mechanisms of action to treat the underlying cause of the disease. Ewing’s sarcoma pipeline is strong, with all of the molecules being first-in-class. These first-in-class molecules have distinct advantages over the currently used products in terms of better disease management. GlobalData, the industry analysis specialist, has released its new report, “Ewing’s Sarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Ewing’s sarcoma market. The report identifies the key trends shaping and driving the global Ewing’s sarcoma market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Ewing’s sarcoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Ewing-Sarcoma-Therapeutics-PipelineAssessment-and-Market-Forecasts-to-2017&ReportType=Ind Visit our report store: http://www.globaldata.com/reportstore For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782